# Paclitaxel

## FORMOXOL inj 60mg/10mL

| 藥物代碼 | IFOR10 |
| :--- | :--- |
| 適應症 | After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma. |
| 副作用 | Bone marrow suppression, peripheral neuropathy, GI disturbances, alopecia, hypersensitivity.Dermatologic: Alopecia \(55% to 96% \)Gastrointestinal: Diarrhea \(16% to 90% \), Inflammatory disease of mucous membrane \(5% to 45% \), Nausea and vomiting, Any grade \(9% to 88% \)Hematologic: Anemia, Any grade \(47% to 96% \), Leukopenia \(90% \), Neutropenia, Any grade \(78% to 100% \), Thrombocytopenia, Any grade \(4% to 68% \)Immunologic: Immune hypersensitivity reaction, Any grade \(2% to 45% \)Musculoskeletal: Arthralgia, MyalgiaNeurologic: Peripheral neuropathy, Any grade \(42% to 79% \) |
| 禁忌 | Hypersensitivity to paclitaxel, polyoxyl 35/polyoxyethylated castor oil \(Cremophor EL\), or any component of the formulation; treatment of solid tumors in patients with baseline neutrophil counts &lt;1,500/mm3; treatment of Kaposi sarcoma in patients with baseline neutrophil counts &lt;1,000/mm3. |
| 藥物保存方式 | 室溫 |
| 用法用量 | 135-175 mg/m2 IV over 3 hr every 3 weeks. Patients must be premedicated dexamethasone, diphenhydramine & cimetidine prior to administration. |
| 肝功能異常 | 需 調 整 劑 量  肝功能不全者發生不良反應機率會增加，請參考仿單對照表調整。 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 稀釋溶液與器具應使用玻璃、聚丙烯\(polypropylene\)、聚烯\(polyolefin\)材質，不可使用含DEHP的PVC塑膠材質。 3. 配製好的輸注溶液濃度在 0.3 - 1.2 mg/mL，室溫下安定性維持 27小時。 4. 注射前應先給予預防過敏的藥物。輸注開始的第一個小時應監測Vital Sign。 5. 曾使用 Paclitaxel發生心臟傳導異常的病人，之後使用Paclitaxel期間應進行連續心電圖監測。 6. 監測CBC。 7.含有蓖麻油成分，容易造成病患過敏反應，施打時應由低速率開始調整，並注意病人反應。 |

## FORMOXOL inj 150mg/25mL

| 藥物代碼 | IFOR25 |
| :--- | :--- |
| 適應症 | After failure of first-line or subsequent chemotherapy for the treatment of metastatic ovarian & breast carcinoma. |
| 副作用 | Bone marrow suppression, peripheral neuropathy, GI disturbances, alopecia, hypersensitivity.Dermatologic: Alopecia \(55% to 96% \)Gastrointestinal: Diarrhea \(16% to 90% \), Inflammatory disease of mucous membrane \(5% to 45% \), Nausea and vomiting, Any grade \(9% to 88% \)Hematologic: Anemia, Any grade \(47% to 96% \), Leukopenia \(90% \), Neutropenia, Any grade \(78% to 100% \), Thrombocytopenia, Any grade \(4% to 68% \)Immunologic: Immune hypersensitivity reaction, Any grade \(2% to 45% \)Musculoskeletal: Arthralgia, MyalgiaNeurologic: Peripheral neuropathy, Any grade \(42% to 79% \) |
| 禁忌 | Hypersensitivity to paclitaxel, polyoxyl 35/polyoxyethylated castor oil \(Cremophor EL\), or any component of the formulation; treatment of solid tumors in patients with baseline neutrophil counts &lt;1,500/mm3; treatment of Kaposi sarcoma in patients with baseline neutrophil counts &lt;1,000/mm3. |
| 藥物保存方式 | 室溫 |
| 用法用量 | 135-175 mg/m2 IV over 3 hr every 3 weeks. Patients must be premedicated dexamethasone, diphenhydramine & cimetidine prior to administration. |
| 肝功能異常 | 需 調 整 劑 量  肝功能不全者發生不良反應機率會增加，請參考仿單對照表調整。 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 稀釋溶液與器具應使用玻璃、聚丙烯\(polypropylene\)、聚烯\(polyolefin\)材質，不可使用含DEHP的PVC塑膠材質。 3. 配製好的輸注溶液濃度在 0.3 - 1.2 mg/mL，室溫下安定性維持 27小時。 4. 注射前應先給予預防過敏的藥物。輸注開始的第一個小時應監測Vital Sign。 5. 曾使用 Paclitaxel發生心臟傳導異常的病人，之後使用Paclitaxel期間應進行連續心電圖監測。 6. 監測CBC。 7.含有蓖麻油成分，容易造成病患過敏反應，施打時應由低速率開始調整，並注意病人反應。 |

